Objective: To examine the prognostic factors and outcomes after several types of treatments in patients with hepatocellular carcinoma (HCC) negative for hepatitis B surface antigen and hepatitis C antibody, so-called "non-B non-C HCC" using the data of a nationwide survey. Background: The proportion of non-B non-C HCC is rapidly increasing in Japan. Methods: A total of 4741 patients with non-B non-C HCC, who underwent hepatic resection (HR, n = 2872), radiofrequency ablation (RFA, n = 432), and transcatheter arterial chemoembolization (TACE, n = 1437) as the initial treatment, were enrolled in this study. The exclusion criteria included extrahepatic metastases and/or Child-Pugh C. Significant prognostic variables determined by a univariate analysis were subjected to a multivariate analysis using a Cox proportional hazard regression model.
H epatocellular carcinoma (HCC) is the third leading cause of cancer-related deaths and fifth most common cancer worldwide.
1,2 Moreover, the incidence and mortality rate have been increasing in the United States and other countries. 3, 4 The prominent etiological factors associated with HCC include chronic infection of hepatitis B virus (HBV) and hepatitis C virus (HCV), and chronic alcohol consumption. Although HCV-related HCC is responsible for the greatest proportion of HCC patients in Japan, 5, 6 many hepatologists note that the proportion of HCC negative for hepatitis B surface antigen (HBsAg) and hepatitis C antibody (HCVAb), so-called "non-B non-C HCC," is rapidly increasing. 7, 8 Indeed, a nationwide follow-up survey by the Liver Cancer Study Group of Japan (LCSGJ) found the proportions of HBV-and HCV-related HCC to have decreased over the previous decade, possibly thanks to the promotion of antiviral therapy, whereas the number of other HCC patients (mostly non-B non-C HCC) have more than doubled during the same period from 6.8% to 17.3%. 9 The exact background or molecular mechanisms for such a sharp increase in the incidence of non-B non-C HCC remain unclear at this point; however, nonalcoholic steatohepatitis (NASH) and metabolic syndrome are suggested to be important risk factors. studies at each institution. Radiofrequency ablation (RFA) began to be more widely used in Japan in 2000. In addition, the data of the Child-Pugh class were requested on the form from the 16th survey. Therefore, the current study used the data from 2000 (16th survey) to 2005 (the latest 18th survey). In this study, 3447 patients for whom the data of hepatitis viral infection status of HBsAg and HCVAb were not available were excluded (Fig. 1) , and 9307 of the remaining 54,003 patients with HCC (17.2%) were negative for both HBsAg and HCVAb (defined as "non-B non-C HCC").
The main purpose of this study was to compare the outcomes after hepatic resection (HR), RFA, and transcatheter arterial chemoembolization (TACE) in the non-B non-C HCC patients. The treatment algorithm for HCC proposed by Japanese guideline 22 indicates these 3 types of therapeutic modalities for patients without extrahepatic metastasis in the degree of liver damage A or B. The treatment algorithm 22 is based on 3 factors: "degree of liver damage" defined by the LCSGJ, 23 "number of tumors," and "tumor diameter." However, Child-Pugh class was adopted instead of the degree of liver damage because the former is globally used to evaluate liver function. Accordingly, the patients with extrahepatic metastasis (n = 944) and those in Child-Pugh C (n = 1028) were excluded. The study also excluded the 2192 patients who underwent the treatment other than the 3 types of therapeutic modalities described earlier. In addition, patients lacking outcome data were excluded (n = 402). Finally, 4741 non-B non-C HCC patients were selected in the current cohort study ( Fig. 1 ) and classified according to the primary treatment into the HR group (n = 2,872), the RFA group (n = 432), and the TACE group (n = 1,437). In fact, the majority of Japanese patients with HCC are treated with 1 of the 3 types of treatment modalities, including surgical treatment, local ablative therapy, and hepatic arterial embolization. The questionnaire sheet of LCSGJ subclassified "Surgical treatment" into HR, liver transplantation, and others. "Local ablative therapy" includes RFA, ethanol injection therapy, microwave coagulation therapy, and others. "Hepatic arterial embolization" is subdivided into TACE (anticancer agents and lipiodol followed by gelatin sponge particles; this method was defined as "TACE" in this study), anticancer agents and lipiodol alone, anticancer agents and gelatin sponge particles alone, and others. The current investigation strictly selected HR, RFA, and FIGURE 1. Flow chart of the patients with non-B non-C hepatocellular carcinoma (HCC) analyzed in this study.
TACE as the most frequently adopted and well-standardized therapeutic strategy from each type of treatment modality in Japan. Indeed, the 18th survey of LCSGJ found that approximately 97% of "Surgical treatment" was HR, 72% of "Local ablative therapy" was RFA, and 76% of "Hepatic arterial embolization" was TACE.
The patients were prospectively followed up at each institution. Most of the patients have been traditionally observed according to the protocol, similar to the Japanese guidelines, 22 in which ultrasonography and measurement of the tumor markers every 3 or 4 months and enhanced computed tomography or magnetic resonance imaging every 6 or 12 months is recommended. The final prognosis of these registered patients was followed until confirmation of death at every survey.
The clinical characteristics among the 3 treatment groups were summarized in Table 1 . All of the 19 variables were significantly different among the groups. Particularly, for the patients in the HR group, the positive percent of habitual alcohol consumption, defined as 86 g or more of ethanol per day over a 10-year period, was significantly lower than that in the RFA and TACE groups. The results of liver function tests, such as indocyanine green retention rate at 15 minutes (ICGR15) and prothrombin activity in this group, were significantly better than those in the RFA and TACE groups. These findings were well coordinated with the status of Child-Pugh class among the 3 groups. On the contrary, the HR and TACE groups had significantly more advanced HCC based on the most of tumor factors, such as the tumor size, tumor markers, and portal venous invasion, than the RFA group. However, the number of tumors in the HR group was the smallest, whereas that in the TACE group was largest. Liverrelated deaths, such as those due to liver failure, in the RFA group were more frequently observed, whereas HCC-related deaths were more common in the HR and TACE groups (Table 1) .
Statistical Analysis
The clinical characteristics among the 3 treatment groups were compared by either the chi-square test or the Kraskul-Wallis test. The survival rate after each treatment was calculated by the Kaplan-Meier method and then was compared by the log-rank test. The Bonferroni correction was applied for the multiple comparisons. Nineteen clinical variables, including type of treatment were evaluated by univariate analysis using a log-rank test to determine the prognostic factors in the patients with non-B non-C HCC. The survival rates after each treatment were stratified according to the TNM staging system defined by the LCSGJ (Table 2 and Table 3) 23 and the Japan Integrated Staging (JIS) score (Table 4) . 24 Because the patients in Child-Pugh C were excluded in this study, JIS score "2" indicated either ChildPugh class A/stage III or Child-Pugh class B/stage II, JIS score "3" indicated either Child-Pugh class A/stage IVA or Child-Pugh class B/stage III, and JIS core "4" indicated Child-Pugh class B/stage IVA.
Continuous variables were divided into 2 groups according to the median value. Significant variables with a P value less than 0.05 by the univariate analysis were subjected to multivariate analysis using a Cox proportional hazard regression model with backward elimination method. 25 All significance tests were 2-tailed, and a P value less than 0.05 was considered statistically significant. All statistical analyses were performed with the Statistical Analysis System (SAS) version 9.1.3 (SAS Inc, Cary, NC). Stage I  T1  N0  M0  Stage II  T2  N0  M0  Stage III  T3  N0  M0  Stage IVA  T4  N0  M0  T1, T2, T3, T4  N1  M0  Stage IVB  T1, T2, T3, T4 N0, N1 M1
The grade for each category is determined individually, and the staging of the disease is determined according to the aforementioned chart.
M1 indicates presence of distant metastasis; N1: presence of lymph node metastasis. 
Prognostic Factors and Survival Rates
Nineteen clinical variables were screened as prognostic factors using a univariate analysis (Table 5 ). Sex and habitual alcohol intake were not selected as prognostic factors, whereas the remaining 17 variables, including age, serum albumin, serum total bilirubin, ICGR15, prothrombin activity, esophageal varices, degree of liver damage, Child-Pugh class, alpha-fetoprotein, protein induced by Vitamin K absence-II (PIVKA-II), tumor number, tumor size, gross classification, portal venous invasion, TNM stage, JIS score, and type of treatment, were significant prognostic factors. With the Child-Pugh class, 5-year survival rates of grades A and B were 58% and 31%, respectively, with statistical significance (P < 0.001; Fig. 2A ). The TNM staging system by the LCSGJ 23 revealed that 5-year survival rates in stages I, II, III, and IVA were 66%, 64%, 46%, and 19%, respectively. A good separation, except stage I vs II, was observed (Fig. 2B) . The 5-year survival rates based on a JIS score of 0, 1, 2, 3, and 4 were 70%, 67%, 44%, 23%, and 0%, respectively. There was a good separation, except JIS score "0" vs "1" (Fig. 2C) . The 5-year survival rates after HR, RFA, and TACE were 66%, 49%, and 32%, respectively (Fig. 2D ). There was no significant difference between the HR group and the RFA group (P = 0.101).
However, when the survival rates were stratified according to the TNM staging system (Fig. 3) , the HR group showed a significantly better prognosis than the TACE group in all 4 stages (stage I to IVA). The RFA group had a significantly better prognosis than the TACE group only in the stage II and III. A comparison between the HR group and the RFA group showed that the HR group had a significantly better prognosis than the RFA group in stage II (Fig. 3B) . However, there were no statistically significant differences between the 2 groups in stages I, III, and IVA. The survival rates in the stage II patients were further stratified according to each T category (Table 3 ) on the basis of the "number of tumors: multiple," "tumor diameter > 2 cm," and "vascular and/or bile duct invasion" by the tumor (Fig. 4) . The HR group had a significantly better prognosis than the RFA group in all 3 T categories. The effectiveness of RFA was almost identical to that of TACE in the stage II patients with multiple tumors (Fig. 4A) and only HR could provide long-term survival in the stage II patients with vascular and/or bile duct invasion (Fig. 4C) .
Similarly, stratifying survival rates according to the JIS score (Fig. 5) showed that the HR group had a significantly better prognosis than the TACE group in all the 4 scores (JIS score "0" to "3"). The RFA group had a significantly better prognosis than the TACE group only in the JIS score "1" and "3." A comparison between the HR group and the RFA group revealed that the former had a significantly better prognosis than the later in the JIS scores "1" and "2" (Figs. 5B, C) . In contrast, the RFA group had an even better prognosis than the HR group in the JIS score "3" (Fig. 5D ). The survival rates in the JIS scores "1," "2," and "3" were further stratified according to each criterion (Table 4) 
Analysis of the Factors Independently Affecting the Survival of Patients
The multivariate initial model provided 11 variables as independent prognostic factors: age, serum albumin, ICGR15, esophageal varices, Child-Pugh class, alpha-fetoprotein, PIVKA-II, tumor size, gross classification, TNM stage, and type of treatment (Supplemental Table 1 , available at http://links.lww.com/SLA/A387). Consequently, the multivariate final model showed 12 variables as independent prognostic factors: the 11 variables described earlier and portal venous invasion ( Table 6 ). The stage IVA and gross classification type 3 (confluent multinodular type) had the highest hazard ratio of 3.83 and 2.86, respectively. In particular, the univariate analysis showed no significant difference between the HR group and the RFA group (Table 5) , but the multivariate analysis revealed a statistically significant difference (hazard ratio: 1.54, P = 0.014) between the 2 groups.
DISCUSSION
In general, it is theoretically difficult to clarify the prognostic factors and therapeutic outcomes after treatments for patients with HCC due to the diversities of tumor stage, degree of chronic liver damage, and therapeutic design, as well as variable etiologic factors of HCC. The present study focused on a relatively small proportion of patients with non-B non-C HCC in Japan, which were further restricted to the patients without extrahepatic metastasis in the ChildPugh A or B, and which principally met the indications for HR, RFA, and TACE based on the treatment guideline. 22 It was obvious that such strict selection of patients requires huge number of patients to be analyzed. Therefore, the present study used the data of a nationwide follow-up survey by the LCSGJ.
The study first compared the clinical backgrounds among the patients who underwent HR, RFA, or TACE as the initial therapy ( Table 1 ). The degree of liver damage in the HR group was significantly lower than those in the RFA and TACE groups. On the contrary, the HR and TACE groups had significantly more advanced HCC than the RFA group. These findings seem to be consistent with those in other studies that included the patients with HCC of varied etiologies of liver disease. However, none of the previous studies have compared the prognostic factors and therapeutic outcomes after the 3 types of treatment modalities with taking such differences in the clinical backgrounds into consideration, possibly due to the limited number of patients.
The study then analyzed the prognostic factors and found that 17 variables, including types of treatment, were significant prognostic factors. Sex and alcohol abuse were not selected as prognostic factors. Although the synergic action of alcohol and HCV infection on hepatocarcinogenesis has been suggested, 26 alcohol consumption alone may not always affect the progression of HCC. The 5-year survival rate in the TACE group (32%) was significantly poorer, whereas there was no significant difference between the RFA group (49%) and the HR group (66%) in the univariate analysis. The 5-year survival rate after TACE in this series (32%) was almost identical to that (34%) based on the data of same nationwide survey (LCSGJ) during the same periods (January 2000-December 2005) but not restricted to the patients with non-B non-C HCC. 27 Hasegawa et al 18 also used the data of the nationwide survey by LCSGJ and compared the prognosis after surgical resection, RFA, and percutaneous ethanol injection. Their evaluation of more than 7000 HCC patients revealed that the time-to-recurrence rate of surgical resection was significantly better than that of RFA or percutaneous ethanol injection. However, the median follow-up period was only 10.4 months, and they did not provide the 5-year survival rate in their study. , and vascular and/or bile duct invasion (C). All comparisons were made by the log-rank test with Bonferroni correction.
FIGURE 5.
Comparisons of the survival rates among the type of treatment. Survival rates were stratified by JIS score "0" (A), JIS score "1" (B), JIS score "2" (C), and JIS score "3" (D). All comparisons were made by log-rank test with Bonferroni correction. 24 The patients in the TACE group had poorer liver functional reserve and more advanced stage of HCC, thus it would be quite natural that overall survival rate in this group had a poorer prognosis. Because the degree of chronic liver damage and the tumor stage were markedly different among the HR, RFA, and TACE groups, the patients were stratified according to the TNM stage. The study also stratified the patients on the basis of the JIS score. 24 Particularly, the HR group had a significantly better prognosis than the TACE group in all 4 stages and the 4 JIS scores even after the stratifications. On the contrary, the prognosis for the patients in the RFA group did not differ significantly in comparison with those in the TACE group in stages I and IVA and JIS scores "0 and 2." The comparison between the HR group and the RFA group showed the HR group to have a significantly better prognosis than the RFA group only in stage II and in JIS scores "1" and "2." These findings suggest that the HR may not offer prognostic advantages over RFA in the early or far advanced stage of non-B non-C HCC patients. Because the stage II patients included the 3 different types of T categories (Table 3) , the survival rates were further stratified on the basis of the T categories (Fig. 4) . The HR group had a significantly better prognosis than the RFA group, especially for the patients with multiple tumors and with vascular and/or bile duct invasion. Long-term survival could be expected only after HR in the stage II patients with vascular and/or bile duct invasion (Fig. 4C) . Similarly, the survival rates in the patients with JIS scores of "1" and "2" were further stratified (Supplemental Figs. 1, 2, available at http://links.lww.com/SLA/A388 and http://links.lww.com/SLA/A389). The effect of HR was observed only in the patients with Child-Pugh class A. Interestingly, the patients in the RFA group (n = 23) in the JIS score "3" subgroup had a significantly better prognosis than the HR group (n = 374). However, after further stratification (Supplemental Fig. 3 , available at http:// links.lww.com/SLA/A390), there was no statistically significant difference between the 2 groups, possibly because of the small number of patients. A possible therapeutic advantage of RFA in the JIS score "3" patients remains to be confirmed.
Surgical hepatectomy provides better survival and lower recurrence rates than RFA for patients with HCC conforming to the Milan criteria in a randomized clinical trial. 19 The authors considered that segment-based anatomic hepatectomy with at least 1 cm of the rim of nontumor parenchyma eradicates both the primary tumor and intrahepatic micrometastasis. There are 2 types of HCC recurrence; one is "early recurrence" due to intrahepatic metastasis and the other is "late recurrence" due to multicentric hepatocarcinogenesis. 28 Recurrence in non-B non-C HCC are mainly dependent on the advanced tumor factors, such as lager tumor size and portal venous invasion, and thus local control of microscopic intrahepatic metastases is required. 29 The importance of an adequate surgical margin for the non-B non-C HCC has also been reported.
14 Therefore, HR, if a segment-based anatomic hepatectomy is deemed to be possible, should be recommended especially for the patients with stage II or the JIS scores "1" and "2" of non-B non-C HCC. Anatomic hepatectomy with adequate surgical margin may decrease the risk of "early recurrence" of non-B non-C HCC due to intrahepatic metastasis. However, the prediction and prevention of "late recurrence" of non-B non-C HCC due to de novo hepatocarcinogenesis may be difficult, because the background liver diseases can be multifactorial and non-B non-C HCC may develop without displaying any features of severe underlying fibrosis. [29] [30] [31] [32] In fact, 13,572 patients underwent HR among the 54,003 total patients for whom the data regarding the hepatitis viral infection status were available (Fig. 1) the histological examination of resected specimens was 1130 of 2495 patients (45%) with HBV-related HCC, 3666 of 7783 patients (47%) with HCV-related HCC, and 788 of 3040 patients (26%) with non-B non-C HCC, indicating that there was a markedly lower incidence of cirrhosis in the non-B non-C HCC patients. Information regarding the possible etiologies of non-B non-C HCC, such as NASH, diabetes mellitus, autoimmune hepatitis, primary biliary cirrhosis, aflatoxin-B1-contaminated food consumption, and hemochromatosis was not available because of lack of inclusion in the questionnaire sheet of this survey. However, according to the reports describing the recent trend of clinical features in Japanese patients with HCC, 10, 33 it is conceivable that a nonnegligible proportion of patients in this study met the criteria for the metabolic syndrome. Potential carcinogenic mediators related to NASH in metabolic syndrome are insulin, lipid peroxidation, free radical oxidative stress, and proinflammatory cytokines. [34] [35] [36] Because HCC associated with metabolic syndrome can often develop without significant liver fibrosis, 31, 32 metabolic syndrome per se may have a direct oncogenic effect, and it may follow a specific molecular pathway of tumorigenesis different from the usual multistep process: fibrosis-cirrhosis-HCC. 31 In this context, specific strategies for screening "late recurrence" may be required for patients with HCC related to metabolic syndrome, even when underlying chronic liver damage is only minimal.
The molecular mechanisms underlying the individual predisposition to non-B non-C HCC may be different, and a better understanding of these mechanisms will lead to improvements in the prevention and early diagnosis of "late recurrence." 9 Because the number of patients with each etiology is limited, a prospective accumulation of non-B non-C HCC patients including information regarding the possible etiologies is essential, and a nationwide multi-institutional study would be desirable.
Finally, 12 independent prognostic factors, including the type of treatment, were identified by using the Cox proportional hazard regression analysis. There was a significant prognostic advantage of HR not only to TACE but also to RFA. Many studies have compared the outcomes after several therapeutic modalities for patients with HCC, 17-21 most of which compared HR versus RFA, whereas a few studies compared HR versus TACE or RFA versus TACE. This is the first study to compare the prognostic factors and outcomes after 3 types of therapeutic modalities at once. All these findings regarding the non-B non-C HCC patients in Japan may be applicable to the HCC patients in the United States and Western countries where the prominent etiological factors are NASH and metabolic syndrome rather than chronic infection of hepatitis viruses.
Limitations of this study include that the data of TNM staging system of the American Joint Committee on Cancer (AJCC)/International Union Against Cancer (UICC) were not available to directly apply the current data to the HCC patients in other countries. However, both the TNM stage by the LCSGJ and the AJCC/UICC were developed on the basis of a survival analysis of patients who underwent HR. Therefore, the applicability of these surgical staging systems to other therapies, such as RFA and TACE, has been a matter of controversy. 37 Comparisons of clinicopathological features and prognostic factors between the non-B non-C HCC and HCC caused by other etiological factors, such as HBV-and HCVrelated HCC, are beyond the scope of this study. Because the current study was not prospectively randomized, the treatment polices were not regulated and the effectiveness of each treatment might not be comparable among the different institutions. In addition, although this study used a multivariate analysis to assess the impact of diverse background on outcomes, there are limits to such a statistical approach.
CONCLUSIONS
This large prospective study based on data derived from a nationwide follow-up survey suggested that HR offers prognostic advantage over RFA and TACE although such advantage may depend upon the degrees of chronic liver damage and the tumor stage.
